Dr Gelareh Eslamian
Consultant Medical Oncologist
MD, MRCP, ESMO
I acquired my medical degree from Babol University in Iran; continued my foundation years and medical training in the Peninsula deanery, Devon and completed my medical oncology training in Wessex, South Yorkshire (Weston Park Hospital), London (Guys and St Thomas' and St George's hospitals) and Kent deaneries.
I specialise in treatment of breast, oesophagus, gastric and pancreato-biliary cancers with a main focus and passion on treating breast cancer. I would encourage active participation in clinical trials and aim to provide the latest available cancer treatment to my patients. I have extensive experience in systemic anti-cancer therapies including chemotherapy, immunotherapy, monoclonal antibodies and endocrine treatments.
I am a core member of the Windsor Breast Multi-Disciplinary Team and the Royal Berkshire UGI MDT. I have extensive experience in treating acutely unwell cancer patients and have a dedicated weekly ward (Acute Oncology). I am the chemotherapy lead for Berkshire Cancer Centre and Chair of the Chemotherapy Steering Group.
I am also interested in medical education and am a clinical supervisor for medical trainees.
Treatment information
Some of the principal treatments carried out by Dr Gelareh Eslamian at Spire include:
Other treatments
- Immunotherapy
- Targeted and endocrine treatments
Get in touch
Additional information
Research and publications
- I have been a co-investigator in numerous oncology phase 3 clinical trials and the following breast cancer trials ARTemis, EMILIA, AZURE, D-CARE, MANTA, OLYMPIA, PERESHONE, ROSCO and PALOMA-2.
-
Dissertation for final year of MD, a research project with “Effects of soy protein on serum hyperlipidaemia”. It was a non-randomised clinical trial study on 98 patients; they were divided in two groups: case (diet+soy) and control (diet). I scored distinction on this research project.
Articles
PEAR Study “243P UK experience of management of pregnancy associated breast cancer”: A national retrospective review of UK practice. ANNALS of ONCOLOGY
September 2020
Poster presentation of PEAR Study “UK experience of the management of Pregnancy -associated Breast cancer: A national retrospective review of UK practice. ESMO 2020, 243P.
Immune checkpoint inhibitor induced large vessel vasculitis, A case report of immune related toxicity post Ipilimumab and Nivolumab, BMJ, Volume 13
May 2020
Poster presentation of “The assessment of Bone Mineral Density (BMD) and fracture risk after three years of adjuvant zoledronic acid in post-menopausal ER+ early breast cancer”. UKBCG.
November 2019
Poster presentation” UK practice in management of pregnancy associated breast cancer”. UKBCG
November 2018
Review article of Eribulin as a novel microtubule targeting agents and its use in breast cancer. “Efficacy of Eribulin in breast cancer, a short report on new emerging data” in OncoTargets and Therapy in February 2017. G. Eslamian, R. Young, C. Wilson.
Poster Presentation “Pertuzumb as part of triple therapy in metastatic HER-2 positive breast cancer”. London UKBCG
November 2017
Financial interests
Contact information
| Private secretary | Donna Gardner |
| Private secretary telephone | 0118 955 3531 |
| Private secretary email | Donna.gardner@spirehealthcare.com |